Physician profile
Sylvia Siegfried
NPI 1447363478
$2,965.37
in general payments reported to CMS, 2019-2025
29 companies · $661 in 2025
The $661 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $247 · 2021: $348 · 2022: $414 · 2023: $480 · 2024: $453 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,508 · Education: $85.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,507.55 |
| Education | $85.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $581.74 | 2019-2025 | Lo Loestrin Fe, Orilissa, Oriahnn |
| Astellas Pharma US INC | $394.43 | 2023-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $247.93 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $233.12 | 2022-2025 | |
| Exeltis, USA INC. | $176.73 | 2019-2025 | Slynd |
| Sumitomo Pharma America, INC. | $167.73 | 2023-2025 | Myfembree |
| Exact Sciences Corporation | $142.11 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Therapeuticsmd, INC. | $141.57 | 2019-2022 | |
| Hologic Sales and Service, LLC | $102.35 | 2019-2025 | Novasure, Myosure Tissue Removal Device |
| Organon LLC | $92.11 | 2022-2025 | Nexplanon |
| Myovant Sciences INC. | $86.97 | 2022 | |
| Biogen, INC. | $69.68 | 2025 | Zurzuvae |
| Pfizer INC. | $69.60 | 2019-2024 | |
| Allergan, INC. | $52.97 | 2019 | |
| Roche Diagnostics Corporation | $45.53 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $40.86 | 2024 | Wavewriter Alpha Prime 16 |
| Kowa Pharmaceuticals America, INC. | $37.32 | 2023 | Seglentis |
| Avion Pharmaceuticals | $37.03 | 2019-2022 | |
| Coopersurgical, INC. | $36.45 | 2020-2022 | |
| Amag Pharmaceuticals, INC. | $33.14 | 2019 | |
| Shield Therapeutics INC | $28.31 | 2023 | Accrufer |
| Scynexis, INC. | $25.06 | 2022 | |
| Fujifilm New Development USA, INC. | $24.61 | 2019 | |
| Evofem Biosciences, INC. | $23.88 | 2021 | |
| Mylan Pharmaceuticals INC. | $22.73 | 2020 | |
| Radius Health, INC. | $16.17 | 2019 | |
| Ascend Therapeutics US, LLC | $14.51 | 2022 | |
| Agile Therapeutics, INC. | $11.53 | 2021 | |
| Kvk-Tech, INC. | $9.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvia Siegfried listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.